TNF α mediated IL-6 secretion is regulated by JAK/STAT pathway but not by MEK phosphorylation and AKT phosphorylation...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Elevated Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF α) are observed in active multiple myeloma (MM).
• Higher levels of IL-6 and TNF α correlate with advanced and aggressive MM.
• The precise signaling mechanisms by which TNF α stimulates IL-6 production in MM cells remain unclear.

Purpose of the Study:

• To elucidate the signaling pathways involved in TNF α-induced IL-6 secretion from MM cells.
• To investigate the role of JAK/STAT and NF-κB pathways in this process.
• To evaluate the therapeutic potential of targeting these pathways in MM.

Main Methods:

• Analysis of bone marrow aspirate samples from MM patients and normal controls.
• Treatment of MM cells with TNF α and various pathway inhibitors (JAK2, IKK β, MEK, p38, PI3K).
• Assessment of protein phosphorylation (MEK, AKT, STAT3) and gene expression (c-Myc, cyclin D1) using Western blotting and siRNA targeting TNF receptors.

Main Results:

• TNF α treatment induced phosphorylation of MEK, AKT, and STAT3 (ser727) in MM cells.
• IL-6 production was significantly reduced by JAK2 and IKK β inhibition, and by siRNA targeting TNF receptors.
• JAK inhibitors effectively decreased the activation of these signaling pathways, impacting c-Myc and cyclin D1 levels.

Conclusions:

• TNF α stimulates IL-6 secretion in MM cells predominantly through JAK/STAT and NF-κB activation.
• Targeting JAK/STAT-mediated NF-κB activation is a promising strategy for controlling MM cell proliferation.
• Inhibiting TNF α-mediated IL-6 secretion represents a potential therapeutic approach for multiple myeloma treatment.